Synaptogenix (NASDAQ:TAOX) Stock Rating Lowered by Wall Street Zen

Synaptogenix (NASDAQ:TAOX) was downgraded by analysts at Wall Street Zen from a “hold” rating to a “sell” rating in a research report issued on Saturday, Wall Street Zen reports.

Separately, Weiss Ratings reiterated a “sell (d-)” rating on shares of Synaptogenix in a research note on Friday, July 17th. One research analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, Synaptogenix has an average rating of “Sell”.

Synaptogenix Price Performance

Shares of TAOX stock opened at $3.90 on Friday. The stock’s 50-day moving average is $3.67 and its 200 day moving average is $4.38. Synaptogenix has a 1-year low of $3.07 and a 1-year high of $10.00. The company has a market cap of $29.17 million, a P/E ratio of -1.01 and a beta of 1.49.

Synaptogenix (NASDAQ:TAOX) last announced its earnings results on Thursday, August 13th. The company reported ($1.83) EPS for the quarter. Synaptogenix had a negative return on equity of 128.51% and a negative net margin of 2,153.97%.The firm had revenue of $0.09 million during the quarter.

Synaptogenix Company Profile

Synaptogenix, Inc operates as a biopharmaceutical company with product candidates in pre-clinical and clinical development. It focuses on developing a product platform based upon a drug candidate called Bryostatin-1 for the treatment of Alzheimer’s disease. The company is also evaluating therapeutic applications of bryostatin for other neurodegenerative or cognitive diseases and dysfunctions, such as fragile X syndrome, multiple sclerosis, and Niemann-pick type C disease. Synaptogenix, Inc has licensing agreements with Stanford University; Icahn School of Medicine at Mount Sinai; and The Board of Trustees of the Leland Stanford Junior University.